FDA Scrutinizes Actos As Lawsuits Mount Against Its Maker
After much criticism, the U.S. Food and Drug Administration (FDA) is finally scrutinizing the connection between the much-prescribed diabetes medication Actos and bladder cancer.
After much criticism, the U.S. Food and Drug Administration (FDA) is finally scrutinizing the connection between the much-prescribed diabetes medication Actos and bladder cancer.This comes at a time when lawsuits being filed against the Japanese pharmaceutical giant could grow to 10,000, according to Actoslawsuitx.com, a Web site that reports on all of the latest developments surrounding the controversial drug.
While consumer advocates are aggressively supporting the FDA’s thorough examination of Actos’ harmful and even fatal side effects, they also continue to criticize the agency for being what they call reactive – rather than proactive.FDA
Slow To Act On Actos Bladder Cancer Connection
Some of them say privately that FDA’s newfound interest in Actos may be too little – too late. They also emphasize that the agency only took action after Actos was pulled off both the German and French markets by the pharmaceutical company itself after European researchers found strong evidence connecting the drug to bladder-cancer deaths.
Moreover, consumer advocates say the seriousness of this move is underscored by the fact that Actos generated $4.8 billion in revenue, which makes up a fourth of Takeda’s total revenue, according to Actos Lawsuit website,
Interim Measures On Actos Bladder Cancer
While the FDA may eventually order Actos, which is also known as pioglitazone, off the U.S. market, it has put in effect the following interim restrictions to medical professionals regarding it being prescribed:
Only prescribe pioglitazone with caution in patients with a prior history of bladder cancer by weighing such use against the unknown risks for cancer recurrence.
Do not prescribe pioglitazone to patients with active bladder cancer.
As can be expected, consumer advocates believe the FDA’s current measures to be woefully inadequate and not a serious enough warning of the Actos’ potentially deadly side effects.
The FDA recently responded to this criticism by issuing the following written statement:“The agency will also conduct a comprehensive review of the results from the French study,” the agency wrote. “FDA will update the public when more information becomes available.”
Advocates respond that it is about time the regulatory agency got up to speed with both Germany and France in protecting its citizens against Actos harmful side effects.
Get Free Expert Legal Advice On Actos
It’s hard to understand how any giant pharmaceutical company like Takeda when facing such a mountain of evidence about its drug’s deadly side effects would continue to let it be sold in United States, the world’s largest market.
Sadly for victims of the drug’s side effects, Takeda is using every legal and financial strategy it can muster to avoid paying victims’ claims against Actos.
That’s why it’s so important if you or a loved one have developed bladder cancer as a result of taking Actos for your diabetes, you should consider seeking legal representation as soon as possible. Time is of the essence -- because Actos lawsuits are subject to a statute of limitations.
For a free, no obligation consultation with an attorney specializing in Actos litigation, simply visit Actoslawsuitx.com and complete the form on the right-hand side of this informational site. An attorney with Actos litigation experience will contact you promptly. Or call toll-free at (888) 770-4343, or by email at email@example.com.
- Contact Information
- Peter Summers
- Media Relations
- Contact via E-mail
This news content may be integrated into any legitimate news gathering and publishing effort. Linking is permitted.
News Release Distribution and Press Release Distribution Services Provided by WebWire.